Xintela AB
1XT
Company Profile
Business description
Xintela AB is a clinical-stage biopharmaceutical company that develops cutting-edge medical products in stem cell therapy and targeted cancer therapy. Its wholly owned subsidiary, Targinta AB, develops First-in-Class therapeutic antibodies targeting integrin α10β1. TARG9, an antibody-drug conjugate (ADC), and TARG10, a function-blocking antibody, are in preclinical development for the treatment of aggressive, difficult-to-treat cancers, including triple-negative breast cancer and brain tumor glioblastoma. Xintela has two clinical studies ongoing with the stem cell product XSTEM and EQSTEM.
Contact
Medicon Village
Lund223 81
SWET: +46 462756500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
11
Stocks News & Analysis
stocks
Investors overlooking ASX share’s potential
International expansion is a distraction from valuable local business.
stocks
Cerebras sees blockbuster demand, setting stage for US AI IPO frenzy
The chipmaker’s IPO priced at $185, well above its initial range, and opened trading at an eye-popping $350.
stocks
What did Morningstar subscribers buy and sell in April?
How the most traded shares in April stack up against our analysts views.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,870.60 | 46.70 | -0.52% |
| CAC 40 | 7,952.55 | 129.72 | -1.61% |
| DAX 40 | 23,950.57 | 505.69 | -2.07% |
| Dow JONES (US) | 49,526.17 | 537.29 | -1.07% |
| FTSE 100 | 10,195.37 | 177.56 | -1.71% |
| HKSE | 25,962.73 | 426.31 | -1.62% |
| NASDAQ | 26,225.14 | 410.08 | -1.54% |
| Nikkei 225 | 61,409.29 | 1,244.76 | -1.99% |
| NZX 50 Index | 12,965.01 | 60.06 | -0.46% |
| S&P 500 | 7,408.50 | 92.74 | -1.24% |
| S&P/ASX 200 | 8,630.80 | 42.70 | -0.49% |
| SSE Composite Index | 4,135.39 | 42.53 | -1.02% |